Immunotherapy firm Forty Seven launches | Chemical & Engineering News
Volume 94 Issue 9 | p. 17 | Concentrates
Issue Date: February 29, 2016

Immunotherapy firm Forty Seven launches

Department: Business
Keywords: oncology, pharmaceuticals, immuno-oncology, cancer, biotech

Cancer-immunotherapy-focused Forty Seven has launched with $75 million in its first round of financing. Forty Seven has licensed the rights to patents covering Hu5F9-G4, a humanized monoclonal antibody against CD47, and other immuno-oncology targets and antibodies. Three Stanford University researchers identified CD47 as an attractive cancer target in 2009 and have since put Hu5F9-G4 into two Phase I studies in people with acute myeloid leukemia or solid tumors.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment